Nephroblastoma overexpressed (Nov) is a novel bone morphogenetic protein antagonist

Annals of the New York Academy of Sciences

Volumn 1116, Issue , 2007, Pages 50-58

  Canalis, Ernesto ^a,b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

BMP antagonists; Bone morphogenetic proteins (BMP); CCN proteins; Nephroblastoma overexpressed; Notch; Osteoblastogenesis; Wnt

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; GLUTATHIONE TRANSFERASE; NEPHROBLASTOMA OVEREXPRESSED; OSTEOCALCIN; UNCLASSIFIED DRUG; WNT3 PROTEIN;

BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CONFERENCE PAPER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE TRANSFORMATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPENIA; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 37249077931     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.055     Document Type: Conference Paper

References (45)

1. BIANCO, P. & R.P. GEHRON. 2000. Marrow stromal stem cells. J. Clin. Invest. 105: 1663-1668.
2. CANALIS, E., A.N. ECONOMIDES & E. GAZZERRO. 2003. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 24: 218-235.
3. GITELMAN, S.E., M. KIRK, J.Q. YE, et al. 1995. Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells. Cell Growth Differ. 6: 827-836.
4. YAMAGUCHI, A., T. ISHIZUYA, N. KINTOU, et al. 1996. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun. 220: 366-371.
5. DE LUCA, F., K.M. BARNES, J.A. UYEDA, et al. 2001. Regulation of growth plate chondrogenesis by bone morphogenetic protein-2. Endocrinology 142: 430-436.
6. GRIMSRUD, C.D., P.R. ROMANO, M. D'SOUZA, et al. 2001. BMP signaling stimulates chondrocyte maturation and the expression of Indian hedgehog. J. Orthop. Res. 19: 18-25.
7. LEBOY, P., G. GRASSO-KNIGHT, M. D'ANGELO, et al. 2001. Smad-Runx interactions during chondrocyte maturation. J. Bone Joint Surg. Am. 83-A(Suppl 1): S15-S22.
8. YAMASHITA, H., P. TEN DIJKE, C.H. HELDIN, et al. 1996. Bone morphogenetic protein receptors. Bone 19: 569-574.
9. DERYNCK, R., Y. ZHANG & X.H. FENG. 1998. Smads: transcriptional activators of TGF-beta responses. Cell 95: 737-740.
10. NOHE, A., S. HASSEL, M. EHRLICH, et al. 2002. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 277: 5330-5338.
11. BRUNET, L.J., J.A. MCMAHON, A.P. MCMAHON, et al. 1998. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455-1457.
12. SHAFRITZ, A.B., E.M. SHORE, F.H. GANNON, et al. 1996. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N. Engl. J. Med. 335: 555-561.
13. GAZZERRO, E., V. GANGJI & E. CANALIS. 1998. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J. Clin. Invest. 102: 2106-2114.
14. PEREIRA, R.C., A.N. ECONOMIDES & E. CANALIS. 2000. Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts. Endocrinology 141: 4558-4563.
15. BRUNKOW, M.E., J.C. GARDNER, N.J. VAN, et al. 2001. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68: 577-589.
16. LOOTS, G.G., M. KNEISSEL, H. KELLER, et al. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 15: 928-935.
17. STAEHLING-HAMPTON, K., S. PROLL, B.W. PAEPER, et al. 2002. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110: 144-152.
18. BRIGSTOCK, D.R.. 2003. The CCN family: a new stimulus package. J. Endocrinol. 178: 169-175.
19. BRIGSTOCK, D.R., R. GOLDSCHMEDING, K.I. KATSUBE, et al. 2003. Proposal for a unified CCN nomenclature. Mol. Pathol. 56: 127-128.
20. GROTENDORST, G.R., L.F. LAU & B. PERBAL. 2000. CCN proteins are distinct from and should not be considered members of the insulin-like growth factor-binding protein superfamily. Endocrinology 141: 2254-2256.
21. ISAACS, N.W. 1995. Cystine knots. Curr. Opin. Struct. Biol. 5: 391-395.
22. GARCIA, A.J., C. COFFINIER, J. LARRAIN, et al. 2002. Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene 287: 39-47.
23. ABREU, J.G., N.I. KETPURA, B. REVERSADE, et al. 2002. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4: 599-604.
24. MERCURIO, S., B. LATINKIC, N. ITASAKI, et al. 2004. Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development 131: 2137-2147.
25. LATINKIC, B.V., S. MERCURIO, B. BENNETT, et al. 2003. Xenopus Cyr61 regulates gastrulation movements and modulates Wnt signalling. Development 130: 2429-2441.
26. IVKOVIC, S., B.S. YOON, S.N. POPOFF, et al. 2003. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130: 2779-2791.
27. MO, F.E., A.G. MUNTEAN, C.C. CHEN, et al. 2002. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol. Cell Biol. 22: 8709-8720.
28. SHIMO, T., S. KUBOTA, N. YOSHIOKA, et al. 2006. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J. Bone Miner. Res. 21: 1045-1059.
29. FRENCH, D.M., R.J. KAUL, A.L. D'SOUZA, et al. 2004. WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am. J. Pathol. 165: 855-867.
30. KUTZ, W.E., Y. GONG & M.L. WARMAN. 2005. WISP3, the gene responsible for the human skeletal disease progressive pseudorheumatoid dysplasia, is not essential for skeletal function in mice. Mol. Cell Biol. 25: 414-421.
31. JOLIOT, V., C. MARTINERIE, G. DAMBRINE, et al. 1992. Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol. Cell Biol. 12: 10-21.
32. PARISI, M.S., E. GAZZERRO, S. RYDZIEL, et al. 2006. Expression and regulation of CCN genes in murine osteoblasts. Bone 38: 671-677.
33. LIN, C.G., S.J. LEU, N. CHEN, et al. 2003. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem. 278: 24200-24208.
34. LIN, C.G., C.C. CHEN, S.J. LEU, et al. 2005. Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J. Biol. Chem. 280: 8229-8237.
35. LAFONT, J., C. JACQUES, G.L. DREAU, et al. 2005. New target genes for NOV/CCN3 in chondrocytes: TGF-beta2 and type X collagen. J. Bone Miner. Res. 20: 2213-2223.
36. SAKAMOTO, K., S. YAMAGUCHI, R. ANDO, et al. 2002. The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J. Biol. Chem. 277: 29399-29405.
37. CIVITELLI, R., E.C. BEYER, P.M. WARLOW, et al. 1993. Connexin43 mediates direct intercellular communication in human osteoblastic cell networks. J. Clin. Invest. 91: 1888-1896.
38. FU, C.T., J.F. BECHBERGER, M.A. OZOG, et al. 2004. CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J. Biol. Chem. 279: 36943-36950.
39. GELLHAUS, A., X. DONG, S. PROPSON, et al. 2004. Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells. J. Biol. Chem. 279: 36931-36942.
40. RYDZIEL, S., L. STADMEYER, S. ZANOTTI, et al. 2007. Nephroblastoma overexpressed (NOV) inhibits osteoblastogenesis and causes osteopenia. J. Biol. Chem. 282: 19762-19772.
41. KRETZSCHMAR, M., J. DOODY & J. MASSAGUE. 1997. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389: 618-622.
42. OSYCZKA, A.M. & P.S. LEBOY. 2005. Bone morphogenetic protein regulation of early osteoblast genes in human marrowstromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology 146: 3428-3437.
43. GAZZERRO, E., R.C. PEREIRA, V. JORGETTI, et al. 2005. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 146: 655-665.
44. GUPTA, R., D. HONG, F. IBORRA, et al. 2007. NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells. Science 316: 590-593.
45. DEREGOWSKI, V., E. GAZZERRO, L. PRIEST, et al. 2006. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling. J. Biol. Chem. 281: 6203-6210.